Jefferies initiated coverage of Hologic (HOLX) with a Hold rating and $85 price target The firm says that while the company is “better capitalized than ever,” the strength of its new business portfolio is unclear as sales continue to underperform peers. Hologic has “noisiness” around its 2025 guide and lingering overhangs that further complicate the nearer-term story, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic research showis Genius AI Detection performs across diverse populations
- Hologic Updates Executive Compensation Agreements for 2025
- Hologic price target raised to $89 from $86 at RBC Capital
- Hologic price target raised to $95 from $93 at Raymond James
- Hologic price target lowered to $87 from $90 at Mizuho
Questions or Comments about the article? Write to editor@tipranks.com